Express Pharma

JUNE 26, 2024

The success of the COVID-19 mRNA vaccines highlighted the major advantages of utilising mRNA technology in vaccine development. Consequently, the FDA has awarded a rising number of review designations to mRNA vaccines in recent years. Implementation of these vaccines is estimated to have prevented 14.4

Vaccines 111

Vaccines Immunization Immunity 111

pharmaphorum

FEBRUARY 25, 2021

Pfizer/BioNTech’s mRNA vaccine against COVID is a technical marvel – but the ultra-cool temperatures required for storage and stability has been tricky to handle. A nasal delivery method will also produce an immune response at the point where the virus enters the body.

Vaccines 111

Vaccines Immunization Immunity 111

Express Pharma

APRIL 7, 2023

People exposed to higher levels of air pollution before the pandemic had lower antibody responses to COVID-19 vaccines, according to a study. The findings, published in the journal Environmental Health Perspectives , provide further evidence on the adverse effects of air pollution on the immune system. Exposure to PM2.5,

Vaccines 110

Vaccines Immunization Immunity Diabetes 110

pharmaphorum

MAY 10, 2021

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . It is also asking for similar data from Moderna, which manufacture a COVID-19 vaccine that like Comirnaty is based on mRNA.

Vaccines 122

Vaccines Labelling Immunization Immunity 122

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccines 119

Vaccines Immunization Immunity 119

European Pharmaceutical Review

APRIL 25, 2023

The R21/Matrix-M malaria vaccine, developed by the University of Oxford , has been approved for use in Ghana (13 April 2023) and was authorised for use in Nigeria on 17 April. How does the R21/Matrix-M vaccine work? This technology has been used successfully in Novavax’s COVID-19 vaccine.

Vaccines 111

Vaccines Immunization Immunity 111

European Pharmaceutical Review

NOVEMBER 1, 2023

adapted COVID-19 vaccine, developed by Novavax for this autumn and winter season. The vaccine, known as Nuvaxovid XBB.1.5, In its decision to recommend the authorisation, the EMA’s human medicines committee (CHMP) assessed laboratory data showing that the adapted vaccine is able to trigger an adequate immune response against XBB.1.5.

Vaccines 105

Vaccines Immunization Immunity 105

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunization Immunity Diabetes 104

pharmaphorum

SEPTEMBER 4, 2020

Sanofi and GlaxoSmithKline have begun clinical trials of their coronavirus vaccine, as AstraZeneca expanded studies of its rival into Japan. The French pharma in April joined forces with the UK’s GSK to produce the vaccine, with Sanofi contributing an antigen that produces the immune reaction.

Vaccines 106

Vaccines Immunization Immunity 106

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. This is an additional ingredient designed to trigger a stronger immune response.

Vaccines 98

Vaccines Immunization Immunity 98

Express Pharma

AUGUST 31, 2023

” AstraZeneca said the deal would support investigational mRNA vaccines early in its pipeline, but the companies have declined to provide any further details. .” ” AstraZeneca said the deal would support investigational mRNA vaccines early in its pipeline, but the companies have declined to provide any further details.

Vaccines 114

Vaccines Immunization Immunity 114

Pharmaceutical Technology

APRIL 14, 2023

Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.

Vaccines 111

Vaccines Immunization Immunity 111

pharmaphorum

DECEMBER 17, 2020

Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).

Vaccines 105

Vaccines Immunization Immunity Hospitals 105

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development. 1 WHO’s analysis was stark.

Vaccines 115

Vaccines Immunization Immunity Drug Development 115

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunization Immunity 97

pharmaphorum

SEPTEMBER 27, 2022

Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.

Vaccines 97

Vaccines Immunization Immunity 97

pharmaphorum

NOVEMBER 25, 2021

A new variant of COVID-19 identified in Botswana with dozens of mutations is being watched closely, amid fears it could be resistant to the effect of currently-used vaccines. — Tom Peacock (@PeacockFlu) November 23, 2021. The post New COVID variant ‘may sidestep vaccine protection’ appeared first on.

Vaccines 116

Vaccines Immunization Immunity 116

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunization Immunity 117

Express Pharma

AUGUST 23, 2023

The study was performed to understand whether the immunity gained after vaccination or a prior infection was less effective or “leaky” in situations where people are exposed to high levels of the virus.

Vaccines 98

Vaccines Documentation Immunization Immunity 98

pharmaphorum

JULY 21, 2022

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on. . ” He said.

Vaccines 105

Vaccines Immunization Immunity 105

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunization Immunity Documentation 98

pharmaphorum

AUGUST 12, 2021

The UK government has started ordering COVID-19 vaccines for a 2022 booster campaign, including a 32 million-dose order for the Pfizer/BioNTech shot, even before third doses for 2021 have been given the go-ahead. The Johnson & Johnson vaccine is also supplied on a no-profit basis. Pricing slammed.

Vaccines 111

Vaccines Immunization Immunity 111

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Immunity 111

Express Pharma

FEBRUARY 1, 2024

Phase 3 trial data results of The R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India, leveraging Novavax’s Matrix-M adjuvant has confirmed high efficacy and supported regulatory approvals and licensure in several African countries. No other vaccine has reported over 55 per cent efficacy in the same age group.

Vaccines 105

Vaccines Immunization Immunity 105

European Pharmaceutical Review

AUGUST 2, 2022

GSK has signed a framework contract with the European Commission’s (EC) Health Emergency Preparedness and Response Authority (HERA) for the reservation of future production and supply of 85 million doses of its pandemic influenza vaccine Adjupanrix [pandemic influenza vaccine (split virion, inactivated, adjuvanted)].

Vaccines 98

Vaccines Immunization Immunity 98

pharmaphorum

MARCH 18, 2021

An EMA advisory committee’s review of AstraZeneca’s COVID-19 has concluded that there is no increase in the overall risk of blood clots with this vaccine. And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”.

Vaccines 105

Vaccines Immunization Immunity 105

European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines 119

Vaccines Immunization Immunity 119

pharmaphorum

JANUARY 31, 2022

It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.

Vaccines 97

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 97

European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

Vaccines 105

Vaccines Immunization Immunity 105

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Subjects in the study will be separated into different groups, depending on the number of months since their first booster.

Vaccines 122

Vaccines Immunization Immunity 122

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunization Immunity 98

pharmaphorum

OCTOBER 30, 2020

Moderna is still preparing for the launch of its COVID-19 vaccine mRNA-1273 – assuming phase 3 trials go to plan – but has already received $1.1 That is the basis for filing for emergency use authorisation (EUA) of the vaccine in the US, according to criteria set out by the FDA. billion in deposits for the shot.

Vaccines 100

Vaccines Immunization Immunity Drug Development 100

Digital Pharmacist

OCTOBER 26, 2022

Food and Drug Administration (FDA) announced its approval of the Boostrix vaccine, commonly known as Tdap (combination of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis) for immunization administration during the third trimester of pregnancy to prevent pertussis in infants younger than two months of age.

Vaccines 98

Vaccines Hospitals Immunization Immunity 98

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

Vaccines 78

Vaccines Immunization Immunity 78

pharmaphorum

SEPTEMBER 3, 2021

Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licensed shot to market. At its recent business update, GSK said it was anticipating peak sales of more than $4 billion for its vaccine if approved.

Vaccines 88

Vaccines Immunization Immunity 88

PharmaShots

APRIL 25, 2023

Numerous pharmaceutical companies have developed and authorized vaccines to provide immunity against COVID-19. Numerous pharmaceutical companies have developed and authorized vaccines to provide immunity against COVID-19. Related Post: Top Performing Drug of 2021 - Darzalex (March Edition) Stay tuned!

Pharmaceutical Companies 56

Pharmaceutical Companies Pharmaceutical Companies Vaccines Immunization 56

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunization Immunity 80